Progesterone deficiency is commonly implicated as an important etiology in pregnancy complications like threatened miscarriage, luteal phase defect (LPD), recurrent pregnancy loss (RPL), etc. LPD characterized by inadequate progesterone secretion during the luteal phase of the menstrual cycle, is associated with implantation failure and early pregnancy loss. Hormonal imbalances are a common element in the etiology of threatened abortion (TA) and RPL. Dydrogesterone, a synthetic progestin, has emerged as a viable treatment option in many reproduction-related disorders, including LPD, TA, RPL, and LPD associated with assisted reproductive technologies (ART). Dydrogesterone has been shown to be effective in preventing miscarriages by maintaining the corpus luteum and promoting endometrial receptivity. This up-to-date article highlights the clinical implications of dydrogesterone pertaining to its use in LPD, TA, and RPL.
